This supplement will allow the Mayo Clinic/University of Minnesota Myeloma DRSC to provide unique resources and support to Dr. Constantine Mitsiades’ supplement to his U01. Dr. Mitsiades is studying the role of glycosylation in drug resistance and in collaboration with the DRSC will analyze myeloma cell lines and drug refractor patient samples for alterations in glycosylation. In addition, the DRSC will provide a unique animal model of myeloma that will be used for in vivo selection of CRISPR targets that mediate drug resistance to immunomodulatory drugs, proteasome inhibitors and T-cell engagers.